104 related articles for article (PubMed ID: 23107612)
21. Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells.
Choi AY; Choi JH; Yoon H; Hwang KY; Noh MH; Choe W; Yoon KS; Ha J; Yeo EJ; Kang I
Eur J Pharmacol; 2011 Oct; 668(1-2):115-26. PubMed ID: 21762691
[TBL] [Abstract][Full Text] [Related]
22. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
Wang Q; Mora-Jensen H; Weniger MA; Perez-Galan P; Wolford C; Hai T; Ron D; Chen W; Trenkle W; Wiestner A; Ye Y
Proc Natl Acad Sci U S A; 2009 Feb; 106(7):2200-5. PubMed ID: 19164757
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
24. Involvement of endoplasmic reticulum stress-mediated CHOP (GADD153) induction in the cytotoxicity of 2-aminophenoxazine-3-one in cancer cells.
Moriya S; Miyazawa K; Kawaguchi T; Che XF; Tomoda A
Int J Oncol; 2011 Oct; 39(4):981-8. PubMed ID: 21667023
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.
Naumann I; Kappler R; von Schweinitz D; Debatin KM; Fulda S
Clin Cancer Res; 2011 May; 17(10):3204-18. PubMed ID: 21459798
[TBL] [Abstract][Full Text] [Related]
26. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
27. Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.
Wagenblast J; Baghi M; Arnoldner C; Bisdas S; Gstöttner W; May A; Knecht R; Hambek M
Oncol Rep; 2008 Nov; 20(5):1207-11. PubMed ID: 18949423
[TBL] [Abstract][Full Text] [Related]
28. GADD153 mediates berberine-induced apoptosis in human cervical cancer Ca ski cells.
Lin JP; Yang JS; Chang NW; Chiu TH; Su CC; Lu KW; Ho YT; Yeh CC; Mei-Dueyang ; Lin HJ; Chung JG
Anticancer Res; 2007; 27(5A):3379-86. PubMed ID: 17970084
[TBL] [Abstract][Full Text] [Related]
29. The novel phloroglucinol derivative BFP induces apoptosis of glioma cancer through reactive oxygen species and endoplasmic reticulum stress pathways.
Lu DY; Chang CS; Yeh WL; Tang CH; Cheung CW; Leung YM; Liu JF; Wong KL
Phytomedicine; 2012 Sep; 19(12):1093-100. PubMed ID: 22819448
[TBL] [Abstract][Full Text] [Related]
30. EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism.
Modernelli A; Naponelli V; Giovanna Troglio M; Bonacini M; Ramazzina I; Bettuzzi S; Rizzi F
Sci Rep; 2015 Oct; 5():15270. PubMed ID: 26471237
[TBL] [Abstract][Full Text] [Related]
31. A novel polysaccharide, isolated from Angelica sinensis (Oliv.) Diels induces the apoptosis of cervical cancer HeLa cells through an intrinsic apoptotic pathway.
Cao W; Li XQ; Wang X; Fan HT; Zhang XN; Hou Y; Liu SB; Mei QB
Phytomedicine; 2010 Jul; 17(8-9):598-605. PubMed ID: 20092988
[TBL] [Abstract][Full Text] [Related]
32. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.
Freudlsperger C; Thies A; Pfüller U; Schumacher U
Anticancer Res; 2007; 27(1A):207-13. PubMed ID: 17352234
[TBL] [Abstract][Full Text] [Related]
33. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
[TBL] [Abstract][Full Text] [Related]
34. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
[TBL] [Abstract][Full Text] [Related]
36. Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines.
Miyahara K; Kazama H; Kokuba H; Komatsu S; Hirota A; Takemura J; Hirasawa K; Moriya S; Abe A; Hiramoto M; Ishikawa T; Miyazawa K
Int J Oncol; 2016 Nov; 49(5):1848-1858. PubMed ID: 27601063
[TBL] [Abstract][Full Text] [Related]
37. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
Wen J; Feng Y; Huang W; Chen H; Liao B; Rice L; Preti HA; Kamble RT; Zu Y; Ballon DJ; Chang CC
Leuk Res; 2010 Jan; 34(1):85-92. PubMed ID: 19608275
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis.
Brüning A; Burger P; Vogel M; Rahmeh M; Friese K; Lenhard M; Burges A
Invest New Drugs; 2009 Dec; 27(6):543-51. PubMed ID: 19039521
[TBL] [Abstract][Full Text] [Related]
39. Genistein-induced apoptosis is mediated by endoplasmic reticulum stress in cervical cancer cells.
Yang YM; Yang Y; Dai WW; Li XM; Ma JQ; Tang LP
Eur Rev Med Pharmacol Sci; 2016 Jul; 20(15):3292-6. PubMed ID: 27467006
[TBL] [Abstract][Full Text] [Related]
40. Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death.
Johnson CE; Dunlop EA; Seifan S; McCann HD; Hay T; Parfitt GJ; Jones AT; Giles PJ; Shen MH; Sampson JR; Errington RJ; Davies DM; Tee AR
Oncogene; 2018 Nov; 37(45):5913-5925. PubMed ID: 29980790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
